Host Modulation Therapy (e.g., low-dose doxycycline)

Type: drug

Status: FDA Approved

Developer: Various (e.g., Periostat by Galderma)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026